Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

Make America Healthy Again starts TOMORROW,” joked Donald Trump Jr. in a post on X sharing the picture. While it is hard to ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...

Merck & Co.’ Inc.’s stock MRK rose 2% premarket Tuesday, after the company reported positive results for a new formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck said a ...

In a significant move towards the liberalization of the healthcare sector, Shanghai's Pudong New Area witnessed the first ...

The Rebecca Foundation, in collaboration with Merck Foundation, has presented 30 brilliant but needy girls with school ...

Koblenz-based MPS is a software specialist for finance and accounting products in public administration with a turnover of ...

CHICAGO -- Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or ...

The pathology and radiology giant is recovering from its post-pandemic malaise and says earnings should improve this year ...

Merck's subcutaneous version of Keytruda succeeded in Phase 3 trials, showing non-inferior results to its IV counterpart. The ...